Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
نویسنده
چکیده
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a novel class of drugs that have been extensively investigated for the treatment of hyperglycemia in type 2 diabetes mellitus (T2DM). These drugs reduce hyperglycemia by blocking renal glucose reabsorption, thereby promoting increased renal glucose excretion. Beyond glycemic control, these drugs have other beneficial effects on cardiovascular (CV) risk factors. The present review discusses the potential role of SGLT2 inhibitors in treating CV complications (acute and chronic) associated with T2DM. FUNDING AstraZeneca Pharma India Ltd.
منابع مشابه
Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
BACKGROUND Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of antidiabetic drugs. PURPOSE To assess the efficacy and safety of SGLT2 inhibitors in adults with type 2 diabetes. DATA SOURCES MEDLINE, EMBASE, and the Cochrane Library from inception through April 2013 without language restrictions; regulatory authorities' reports; and gray literature. STUDY SELECTION Randomi...
متن کاملMetabolic and hemodynamic effects of sodium‐dependent glucose cotransporter 2 inhibitors on cardio‐renal protection in the treatment of patients with type 2 diabetes mellitus
The specific sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) inhibit glucose reabsorption in proximal renal tubular cells, and both fasting and postprandial glucose significantly decrease because of urinary glucose loss. As a result, pancreatic β-cell function and peripheral insulin action significantly improve with relief from glucose toxicity. Furthermore, whole-body energy metab...
متن کاملEffects of Sodium‐Glucose Cotransporter 2 Inhibitors on 24‐Hour Ambulatory Blood Pressure: A Systematic Review and Meta‐Analysis
BACKGROUND Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a novel class of antihyperglycemic agents that improve glycemic control by increasing glycosuria. Additional benefits beyond glucose lowering include significant improvements in seated clinic blood pressure (BP), partly attributed to their diuretic-like actions. Less known are the effects of this class on 24-hour ambulatory BP, wh...
متن کاملSGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors1
Background: Sodium glucose cotransporter-2 (SGLT2) inhibitors are recommended by the American Diabetes Association (ADA) for the treatment of type 2 diabetes as one of six second-line therapy options after initial therapy with metformin. In addition, they have been studied in combination with insulin as a potential option for treating patients with type 1 diabetes. These medications act by inhi...
متن کاملSGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy
Diabetic nephropathy (DN) is a major cause of end-stage renal disease (ESRD) worldwide. Glycemic and blood pressure (BP) control are important but not sufficient to attenuate the incidence and progression of DN. Sodium-glucose cotransporter (SGLT) 2 inhibitors are a new class of glucose-lowering agent suggested to exert renoprotective effects in glucose lowering-dependent and independent fashio...
متن کامل